SELF/Trigger Finger Injections

▼This page is a part of the Anesthesia and Critical Care Curriculum by WACS and SELFPlease see the Intuitive Foundation Terms of Use and do not edit without permission.

   ⚠️In Development: Module actively being built.

The procedure for trigger finger treatment involves identifying the affected flexor tendon sheath, localizing the A1 pulley, and delivering a precise corticosteroid or anesthetic injection or performing a small release if needed. This training module will focus on knowledge materials such as anatomical landmark recognition and psychomotor skills like needle placement at the correct angle and depth, and safe injection technique while avoiding neurovascular injury.

Self-assessment

Please complete the following: Quiz

• Describe the indications, contraindications, and risk factors that guide decision-making in trigger finger management.
• Identify the essential supplies and explain correct patient positioning and site marking for safe preparation.
• Explain the anatomical landmarks of the A1 pulley and the technical steps for accurate corticosteroid injection.
• Compare available anesthesia options and outline considerations for safe use in patients with comorbidities.
• Summarize the required documentation following the procedure and the key aspects of patient education.
• Recognize common complications of injection and explain their early detection and management.

A corticosteroid injection for trigger finger is a minimally invasive procedure in which a fine needle is introduced into the flexor tendon sheath at the level of the A1 pulley, located at the metacarpophalangeal (MCP) crease. After sterile preparation, a mixture of corticosteroid and local anesthetic is delivered directly into the tendon sheath, reducing inflammation and allowing smoother gliding of the flexor tendon. In selected cases where injections fail or the condition is recurrent, a small surgical release is performed through a limited incision over the A1 pulley, dividing the constricting sheath while preserving adjacent neurovascular structures.

Unlike systemic therapy or splinting, the goal of the procedure is not only symptomatic relief but also correction of the mechanical cause of triggering—stenosis at the A1 pulley. It offers direct, localized treatment with high success rates, providing rapid pain reduction, improved range of motion, and restoration of hand function. Because it is performed through a small puncture or incision, recovery is faster, complications are fewer compared to open extensive surgery, and escalation to surgical release is available if nonoperative treatment fails.

Trigger finger, or stenosing tenosynovitis, is caused by thickening or constriction of the flexor tendon sheath at the A1 pulley, producing pain and locking during finger movement.

The decision to perform an injection or release must begin with a clear understanding of indications and contraindications. Indications include persistent finger locking or catching with pain that interferes with daily function, failure of conservative therapy such as splinting or NSAIDs, or recurrence in patients with occupational or daily repetitive gripping demands. Contraindications include suspected infection at the injection site, hypersensitivity to corticosteroids or anesthetic agents, and uncorrected coagulopathy. Special caution should be exercised in patients with poorly controlled diabetes, as corticosteroid injections can significantly worsen glycemic control, and in those with rheumatoid arthritis, as tenosynovitis may represent a systemic inflammatory process rather than isolated pathology.

When evaluating risk factors, practitioners should recognize that middle-aged women, particularly those over 40 years of age, with occupations or tasks requiring repetitive gripping, are disproportionately affected. Additionally, comorbid conditions such as diabetes mellitus, hypothyroidism, and inflammatory arthropathies increase risk both for occurrence and recurrence after treatment. Practitioners should take careful history not only of current symptoms, but also occupational and daily activity patterns, since manual workers performing forceful repetitive gripping (e.g., farming, mechanics, factory work) often require earlier injection or release due to higher recurrence and poorer response to splinting, whereas those in lighter tasks such as typing may benefit from conservative therapy before invasive intervention.

A strong understanding of finger involvement patterns guides diagnostic suspicion: the thumb is most commonly affected, followed by the middle finger, then ring, index, and rarely the little finger. Bilateral involvement may occur, particularly in diabetics, and should prompt examination of all digits rather than only the symptomatic finger. The differential should also include other causes of painful finger motion, such as MCP joint synovitis, Dupuytren’s contracture, and early carpal tunnel syndrome.

Finally, practitioners must decide between corticosteroid injection and surgical release. Injections are the first-line procedural treatment, with resolution rates of 60–90%, though multiple injections may be required. Surgery is reserved for cases of recurrence after two properly performed injections, severe contracture of the finger with limited extension, or in pediatric patients where injections are less effective. Outcomes and recurrence rates should be discussed transparently with patients before proceeding.

Before initiating the procedure, informed consent must be obtained and documented, with clear communication of the goal (relief of pain and triggering), benefits (non-invasive or minimally invasive intervention with good efficacy), risks (infection, tendon rupture, neurovascular injury, recurrence, steroid-related side effects), and alternatives (observation, splinting, systemic anti-inflammatory therapy, surgery). Patients should be informed that while relief may be immediate with local anesthetic, corticosteroid effect can take several days to manifest, and recurrence remains a possibility.

The equipment and supply list should be complete and organized in order of use.

Patient positioning is critical. The patient should be seated comfortably with the forearm supported on a pillow or armrest, hand supinated and relaxed. The wrist and MCP joints should be in neutral, allowing clear access to the palmar surface. The affected digit should be visible from base to tip, with the MCP crease unobstructed. Incorrect positioning leads to unstable hand support, patient discomfort, and increased risk of inaccurate injection.

Site marking is done with a sterile pen at the level of the A1 pulley, located just distal to the palmar crease at the MCP joint. Palpation during active finger flexion and extension helps confirm the flexor tendon sheath. The practitioner should confirm correct finger identification before draping. A brief "time-out" using a WHO-style checklist—verifying patient identity, procedure, side, and drug—is performed before skin preparation.

The key anatomical landmark is the A1 pulley, located at the level of the MCP crease, overlying the flexor tendon sheath. Care must be taken to avoid neurovascular bundles, which run on either side of the tendon. Palpation of the tendon during flexion allows confirmation of its midline position, ensuring safe injection away from lateral neurovascular structures.

Sterility is paramount. The skin is prepared with povidone iodine or chlorhexidine solution, applied in concentric circles outward from the injection site. The site is allowed to dry fully before proceeding. A sterile drape is placed to isolate the field. Any break in sterility should prompt replacement of instruments or re-preparation of the skin.

When performing a corticosteroid injection, a 23–27G needle is introduced at a 30–45° angle with bevel up, aiming cranially. Entry is made just proximal to the MCP crease, targeting the flexor tendon sheath. The practitioner should feel a subtle "give" as the sheath is penetrated. Aspiration must be performed to rule out intravascular placement. If the needle moves with tendon flexion, it has entered the tendon itself and should be withdrawn slightly. Once correctly placed, 0.5 ml of corticosteroid mixed with 0.5 ml plain xylocaine is injected slowly; resistance or pain suggests improper placement.

For surgical release (reserved for recurrent or resistant cases), a small transverse incision is made at the MCP crease overlying the A1 pulley. Care is taken to avoid digital nerves, with gentle spreading dissection until the pulley is identified. The pulley is incised longitudinally to relieve constriction, while preserving adjacent structures. The wound is irrigated and closed with fine absorbable sutures or left open if very small. Meticulous hemostasis and minimal dissection reduce risk of stiffness and scarring.

Anaesthesia may be local infiltration, topical application, or a combination. Plain 2% xylocaine is most commonly infiltrated around the planned injection site in a volume of 0.5–1 ml. Care must be taken to avoid over-infiltration, which can distort tissue planes and obscure anatomical landmarks. After injection, a 2–3 minute pause ensures adequate onset before the procedure.

Topical anesthesia, such as EMLA cream, may be applied under occlusion for 30–45 minutes before injection. Alternatively, ethyl chloride spray can be used immediately before the procedure for surface numbing. These are useful adjuncts in anxious patients or those with low pain thresholds, but do not replace infiltration when a corticosteroid injection is planned.

In some cases, a combination of xylocaine with corticosteroid in the same syringe is employed to provide immediate analgesia and facilitate early finger mobilization. The mixing must be done under sterile conditions with exact doses measured. For pediatric patients or those with extreme procedural anxiety, sedation or regional anesthesia may be indicated, though this is less common.

Practitioners should also assess for contraindications to local anesthesia, such as allergy to amide anesthetics, and counsel diabetic patients that steroid injections may cause temporary hyperglycemia. A brief test dose may be administered if allergy is uncertain. Clear communication with the patient during anesthesia administration reassures and ensures cooperation.

Once the injection or minor release is complete, the needle is withdrawn smoothly and gentle pressure applied with sterile gauze to reduce bleeding. A clean sterile bandage is placed, and a neck sling may be provided to reduce hand use for the first 24 hours. Patients should be instructed to begin gentle finger mobilization the following day to prevent stiffness, unless otherwise contraindicated.

Documentation is essential and must include: patient identifiers, finger treated, side (left/right), drug(s) administered with dose, lot number, and route, details of local anesthetic used, site of injection, and any intra-procedural complications. Patient education provided should also be documented, including guidance on signs of infection, recurrence, or adverse effects.

Potential complications must be anticipated and addressed early. Infection is rare but serious; patients should be advised to return immediately if swelling, redness, or fever develop. Tendon rupture, though uncommon, presents as sudden loss of flexion and requires urgent surgical evaluation. Neurovascular injury presents as numbness or persistent pain and must be recognized promptly. Recurrence rates after injection can be up to 30%, especially in diabetics. Persistent stiffness may result from prolonged immobilization or excessive scar tissue formation.

Patients should be scheduled for follow-up at 2–4 weeks to assess resolution of symptoms and monitor for complications. If symptoms persist after two injections, surgical release should be considered. A proactive discussion about recurrence and the potential need for surgery builds trust and ensures continuity of care.

In resource-limited settings, practitioners may face shortages of sterile drapes, topical anesthetics, or preloaded corticosteroid syringes. A pragmatic approach includes the use of clean reusable cloths autoclaved to substitute for disposable drapes, reliance on thorough povidone-iodine antisepsis when alcohol swabs are unavailable, and using plain lidocaine infiltration without adjunctive topical agents. When only larger-bore needles are available, extra care should be taken to maintain correct depth and angle to avoid intratendinous placement.

Developer Instructions

Complete with knowledge materials broken up by lesson / topic.

Self-assessment

Please complete the following: Quiz

Developer Instructions

In a brief paragraph or two, describe your simulator. What does it look like? What does it do? What are the layers or elements? Work on this section after completing the simulation requirements

• BUILD INSTRUCTIONS
• PRACTICE INSTRUCTIONS